Canceromatosis modelling of intraperitoneal implantation of solid tumours in mice or human

In the work there are described the parameters of a canceromatosis by the intraperitoneal implantation of the solid tumors: Lewis lung carcinoma (LLC) to syngeneic regular males of C57Bl6j mice and human subcutaneous breast cancer (BC) xenografts BC-1 to immunodeficient females of mice Balb/c nude. There was shown aggressive LLC canceromatosis which was realized as the solid tumor nodule (from 30-40 singles to the total) growths on a peritoneum (parietal or visceral) and a mesenteries or of the intestinal lymphoid nodules, development of space-occupying ascites (to 3.0 ml), and death of mice for 12-14 days. This model is characterized as moderately sensitive to paclitaxel (inhibition of tumor growth by 84% and increasing of life span of mice up to 46%). BC-1 canceromatosis was low aggressive with development of the single (solitary) solid tumor nodule on a peritoneum in the place of implantation and reaching within 3 weeks of average volume to 300 mm3 without accumulation of ascites, decreasing of the life span or death of mice. This model is characterized as moderately sensitive to paclitaxel with inhibition of the tumor growth by 85%. The obtained data give the ground to consider that both intraperitoneal solid tumors represent themselves to be sensitive to systemic chemotherapy for the model of canceromatosis differing in various aggressiveness of a course and specific symptomatics of the process. For an aggressive LLC canceromatosis the evidential base of efficiency has to be formed on the basis of inhibition of growth of the peritoneal tumor nodules in peritoneal cavity and accumulation ofperitoneal ascites, and also the increase of the mice life span, for a nonaggressive BC-1 canceromatosis - inhibition of the growth of the peritoneal tumor nodule.

canceromatosis, parameters, intraperitoneal implantation, transplanted tumors of mice or human